A Real-Life Study to Assess the Efficacy and Safety of Immune Checkpoint Inhibitors in Elderly and Frail Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 18 Oct 2019

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

18 Oct 2019 New trial record
10 Sep 2019 Results assessing the efficacy and safety of immune checkpoint inhibitors (nivolumab or pembrolizumab) in elderly and frail, advanced non-small cell lung cancer patients, were presented at the 20th World Conference on Lung Cancer.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com